DXRX logo element
DXRX logo element
Reports

Non-Small Cell Lung Cancer (NSCLC) PD-L1 Testing Landscape Challenges in the Context of Upcoming In Vitro Diagnostics Regulation (IVDR) Implementation

Tue Aug 23 2022

In this conference poster, Diaceutics explore the implementation of the In Vitro Diagnostic Device Regulation (IVDR) (EU 2017/746), which comes into full effect in May 2022, could potentially disrupt current PD-L1 testing practice for all indications as companion diagnostics will, for the first time in the EU, be regulated.

Non-Small Cell Lung Cancer (NSCLC) PD-L1 Testing Landscape Challenges in the Context of Upcoming In Vitro Diagnostics Regulation (IVDR) Implementation

Non-Small Cell Lung Cancer (NSCLC) PD-L1 Testing Landscape Challenges in the Context of Upcoming In Vitro Diagnostics Regulation (IVDR) Implementation

Article
Read full article

This poster address the Non-Small Cell Lung Cancer PD-L1 testing landscape. To view the poster, sign in to DXRX.

Authors: Gwendolyn Courtois MSc2, Lauren Parnham2, Katherine E. Keating PhD2, Peter Riccelli PhD1, Dave Smart PhD2, Susanne Munksted MSc2, Jordan Clark MPhil2, Keith Kerr MD, FRCPath3

Non-Small Cell Lung Cancer (NSCLC) PD-L1 Testing Landscape Challenges in the Context of Upcoming In Vitro Diagnostics Regulation (IVDR) Implementation

Join DXRX or login to read more on this topic
Read full article